digital currency rmb Block

The OpenAI webpage shows that API, ChatGPT and Sora are all running normally.The OpenAI webpage shows that API, ChatGPT and Sora are all running normally.Botuo Bio: Adjust the profit distribution plan for the first three quarters of 2024. Botuo Bio announced that the total amount of cash dividends to be distributed in the company's profit distribution for the first three quarters of 2024 was adjusted from RMB 52.2583 million to RMB 53.2083 million. Before the adjustment, the company's total share capital was 105 million shares after deducting the shares in the company's repurchase special securities account, and a total cash dividend of 52.2583 million yuan was planned to be distributed. After adjustment, the company's total share capital is 107 million shares, of which 250,000 shares are repurchased in the special securities account, and the total number of shares actually participating in the profit distribution of the company is 106 million shares, with a total cash dividend of 53,208,300 yuan.

In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)Hebang Bio established a mining engineering company in Leshan, Sichuan. The enterprise search APP shows that Leshan Hebang Mining Engineering Co., Ltd. was established recently, with Fei Wang as the legal representative and a registered capital of 10 million yuan. Its business scope includes: mineral resources reserve evaluation service; Mineral resources reserve estimation and report preparation services; Geological disaster management services, etc. Enterprise investigation shows that the company is wholly owned by Hebang Bio.Li Ka-shing's H-share shareholding in China Postal Savings Bank decreased from 5.07% to 4.96%.

Treasury futures turned green for 30 years, and treasury futures turned down. The 30-year main contracts turned green and fell by 0.03% to 116.94. The 10-year main contract was reported at 108.17, and the increase narrowed to 0.02%.Huaxin Securities: China Unicom's operating income grew steadily and maintained its "buy" rating. Huaxin Securities Research Report pointed out that since the beginning of this year, China Unicom (600050.SH) has seen steady growth in operating income, rapid improvement in profitability, steady expansion of user scale and continuous consolidation of network foundation, laying a more solid foundation for high-quality development of enterprises. Communication and digital intelligence services are driven by two wheels, injecting vitality into the company's performance. Looking forward to the whole year, the company will adhere to the general tone of steady progress, promote the network to be new, technology to be new and service to be new, strive to achieve the performance goal of steady growth of operating income and double-digit growth of profits throughout the year, take greater steps in high-quality development, and accelerate the construction of a world-class science and technology service enterprise with global competitiveness. With the gradual expansion of user scale and the drive of digital transformation, the company will benefit from the continuous improvement of revenue and profit and maintain the "buy" investment rating.The Japanese yen faces new risks. Strategists worry that the Bank of Japan may wait until March or later to raise interest rates. A new risk is emerging for the Japanese yen. Foreign exchange strategists in Tokyo warn that the Bank of Japan may wait until March or later next year to raise interest rates. On Wednesday, the market tasted this danger, and the yen fell to its lowest level in more than two weeks as traders responded to a Bloomberg report that the Bank of Japan is known to think that it is no harm to raise interest rates later. The yen only fell to 152.82 against the dollar, and the market is still debating whether the Bank of Japan will take action at its next meeting on December 19 or about a month later. Shusuke Yamada, head of Japan's foreign exchange and interest rate strategy at Bank of America in Tokyo, said that if policymakers put off raising interest rates for a longer time, the situation would be very different. "If the interest rate hike is postponed until March, the yen carry trade is likely to make a comeback," Yamada said on Thursday. "The yen is likely to fall again to a level just below the 157 mark hit in 155 or November."